137 related articles for article (PubMed ID: 9001836)
1. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
[TBL] [Abstract][Full Text] [Related]
2. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
Braun S; van der Wall EE; Emanuelsson H; Kobrin I
J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
[TBL] [Abstract][Full Text] [Related]
4. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Kobrin I; Charlon V; Lindberg E; Pordy R
Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
[TBL] [Abstract][Full Text] [Related]
5. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
[TBL] [Abstract][Full Text] [Related]
6. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic angina pectoris with combination mibefradil and beta-blocker therapy.
Alpert JS
Clin Cardiol; 1998 Feb; 21(2):129. PubMed ID: 9491954
[No Abstract] [Full Text] [Related]
8. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
Oparil S; Bernink P; Bursztyn M; Carney S; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):12C-19C. PubMed ID: 9286849
[TBL] [Abstract][Full Text] [Related]
9. Additional antianginal and anti-ischemic efficacy of mibefradil in patients concomitantly treated with long-acting nitrates for chronic stable angina pectoris.
Frishman WH; Bittar N; Glasser S; Habib G; Smith W; Pordy R
Clin Cardiol; 1998 Jul; 21(7):483-90. PubMed ID: 9669057
[TBL] [Abstract][Full Text] [Related]
10. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
[TBL] [Abstract][Full Text] [Related]
11. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
[TBL] [Abstract][Full Text] [Related]
12. Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats.
Sandmann S; Spitznagel H; Chung O; Xia QG; Illner S; Jänichen G; Rossius B; Daemen MJ; Unger T
Cardiovasc Res; 1998 Aug; 39(2):339-50. PubMed ID: 9798519
[TBL] [Abstract][Full Text] [Related]
13. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
Bernink PJ; Prager G; Schelling A; Kobrin I
Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
[TBL] [Abstract][Full Text] [Related]
15. Differential properties of mibefradil in hypertension and angina.
Kobrin I
J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
[TBL] [Abstract][Full Text] [Related]
16. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
Alpert JS; Kobrin I; DeQuattro V; Friedman R; Shepherd A; Fenster PE; Thadani U
Am J Cardiol; 1997 Apr; 79(8):1025-30. PubMed ID: 9114758
[TBL] [Abstract][Full Text] [Related]
17. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris.
Portegies MC; Schmitt R; Kraaij CJ; Braat SH; Gassner A; Hagemeijer F; Pozenel H; Prager G; Viersma JW; van der Wall EE
J Cardiovasc Pharmacol; 1991 Nov; 18(5):746-51. PubMed ID: 1723772
[TBL] [Abstract][Full Text] [Related]
18. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.
Alpert JS; Bakx AL; Braun S; Frishman WH; Schneeweiss A; Tzivoni D; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):20C-26C. PubMed ID: 9286850
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I
Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea.
Heitmann J; Grote L; Knaack L; Köhler U; Hinder M; Peter JH
Eur J Clin Pharmacol; 1998; 54(9-10):691-6. PubMed ID: 9923569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]